Status:
ACTIVE_NOT_RECRUITING
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Lead Sponsor:
Prisma Health-Upstate
Collaborating Sponsors:
Cereno Scientific AB
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
Brief Summary
Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utiliz...
Eligibility Criteria
Inclusion
- Participation in the CS1-004 clinical trial
Exclusion
- Inability to undergo a CT pulmonary angiography scan (i.e., claustrophobia)
- Individuals who are pregnant or who become pregnant during the sub-study
- eGFR \<30 mL/min/1.73m2 as calculated by Modification of Diet in Renal Disease (MDRD)
- Allergy to Iodine contrast agents
Key Trial Info
Start Date :
March 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2026
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06907693
Start Date
March 14 2025
End Date
January 15 2026
Last Update
January 7 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prisma Health
Greenville, South Carolina, United States, 29605